Catalyst Pharmaceuticals Inc (NASDAQ:CPRX)
| 16.58 Delayed Data As of Mar 31 |  +0.12 / +0.73%Today’s Change | 6.15 Today|||52-Week Range 22.11 | -10.86% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $1.7B |
Company Description
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.
Contact Information
Catalyst Pharmaceuticals, Inc. 355 Alhambra Circle Coral Gables Florida 33134 |
Employees
Shareholders
| Mutual fund holders | -- |
| Individual stakeholders | -- |
| Other institutional | -- |
Top Executives
| Patrick J. McEnany | Chairman, President & Chief Executive Officer |
| Steven R. Miller | Chief Operating & Scientific Officer |
| Alicia Grande | CFO, Treasurer, Principal Accounting Officer & VP |
| Gary Ingenito | Chief Medical & Regulatory Officer |
| Stanley Iyadurai | Senior VP-Medical Affairs & Drug Discovery |
